A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
Clinical trial NCT06838273 · RECRUITING
Trial details
- NCT number
- NCT06838273
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-24
- Primary completion
- 2028-12-01
- Enrollment
- 720
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.